Founded in 1989 and with headquarters in Ann Arbor, Michigan, Aastrom Biosciences is dedicated to the development of treatments for critical cardiovascular diseases. Aastrom is currently evaluating its autologous cellular therapies in late-stage U.S. clinical trials in the treatment of critical limb ischemia (CLI) and dilated cardiomyopathy (DCM). These critical diseases are associated with significant morbidity and mortality and very limited treatment options.
In this interview, Tim Mayleben offers his prospective on the potential market for ixmyelocel-T, the company's lead product candidate for critical limb ischemia and dilated cardiomyopathy.